We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Immunoassay, Mini Mass Spec Combined for Malaria Detection

By LabMedica International staff writers
Posted on 01 Nov 2022

Currently, several different technologies are available for diagnosing malaria, but each has drawbacks. More...

PCR, for instance, is highly sensitive and specific, but it requires upfront sample processing and specialized equipment. While point-of-care and home PCR testing has come to market in recent years, these assays are quite expensive.

There are also rapid antigen tests for malaria, but these tests can be expensive. Microscopy is the traditional gold standard for diagnosing malaria, but it is labor intensive and subjective as well as technically challenging. A protein detection workflow that combines paper-based immunoassays with miniaturized mass spectrometry to enable diagnostic testing in resource-constrained areas has been developed.

Biochemists at Ohio State University (Columbus, OH, USA) used ionic probe technology for malaria detection and suggested it could be applied for large-scale surveillance and screening for the disease. The probes provide a more stable alternative to reagents used in conventional immunoassays, making them potentially useful for work in areas where cold storage is not widely available. The probes remain stable for several weeks under ambient conditions and are designed to release, upon treatment with ammonium hydroxide, mass tags that can be detected using paper spray ionization mass spectrometry.

The investigators synthesized pH-sensitive ionic probes and coupled them with monoclonal antibodies specific to the Plasmodium falciparum histidine-rich protein 2 (PfHRP2) malaria antigen. They then used the antibody-ionic probe conjugates in a paper-based immunoassay to capture PfHRP2 antigen from untreated whole blood. After the immunoassay, the bound ionic probes were cleaved, and the released mass tags were analyzed through an on-chip paper spray mass spectrometry strategy.

The test was able to detect the malaria antigen PfHRP2 in untreated human serum at levels down to 0.216 nmol/L, below the 0.227 nmol/L sensitivity threshold recommended by the World Health Organization for evaluating symptomatic patients. In terms of cost, the test is currently more expensive than the low end of the rapid antigen market, but it is expected costs will come down once the test is fully developed and being manufactured at scale. The team used a Continuity miniature mass spectrometer (BaySpec, Jose, CA, USA).

Abraham Badu-Tawiah, PhD, a Professor of Chemistry and senior author of the study, said, “Bigger mass spectrometers need to run continuously to maintain performance. Not so with portable instruments. The portable mass spectrometer is robust and can be turned it off when not in use, and turn it on when needed. It takes only 10 minutes to get it ready for analysis.”

The authors concluded that the stability and sensitivity of the developed paper-based immunoassay platform will allow miniature mass spectrometers to be used for point-of-care malaria detection as well as in large-scale surveillance screening to aid eradication programs. The study was published on October 4 2022 in the journal Analytical Chemistry.

Related Links:
Ohio State University
BaySpec 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.